Novo Nordisk has launched an oral version of its weight-loss drug Wegovy in the U.S., offering a convenient alternative to injections. The pill, containing semaglutide, was approved by the FDA in December and is available for $149 per month for initial doses, with prices increasing later in April. Clinical trials show significant weight loss benefits, making it a notable innovation in obesity treatment.
Vanda Pharmaceuticals received FDA approval for NEREUS (tradipitant), the first new drug in over 40 years for preventing motion sickness-induced vomiting, supported by robust clinical trial data showing significant efficacy and safety, marking a major advancement in treatment options for this condition affecting millions.
Novo Nordisk received FDA approval for Wegovy, the first oral GLP-1 medication for weight loss, which could significantly impact the obesity treatment industry by offering a more convenient option and potentially increasing market share amid rising competition and pricing pressures.
Novo Nordisk's stock faced challenges in 2025 due to competition and demand issues, but the FDA approval of its Wegovy pill and plans to launch an oral version in 2026 present a strategic comeback opportunity, prompting investors to consider whether to buy, sell, or hold the stock.
The US FDA has approved a pill version of Wegovy, a weight-loss drug by Novo Nordisk, offering a convenient once-daily alternative to injections with similar effectiveness, potentially boosting the company's sales amid market competition.
The FDA has approved the first daily oral medication version of Wegovy, a popular weight-loss drug, giving Novo Nordisk an advantage over Eli Lilly, whose similar drug is still under review. The pill, containing semaglutide, has shown significant weight loss in clinical trials and is expected to be available soon, potentially expanding access and reducing costs for obesity treatments.
The FDA has approved the first oral GLP-1 pill for weight loss, developed by Novo Nordisk, which offers a more convenient and potentially cheaper alternative to injections, with clinical trials showing significant weight loss results.
The FDA has approved a daily pill version of Wegovy, a popular anti-obesity drug by Novo Nordisk, offering an alternative to the weekly injection with similar effectiveness in weight loss, and expected to be available in early January for $149 per month.
The FDA has approved a daily oral version of Wegovy, a GLP-1 weight-loss drug by Novo Nordisk, offering a new, more convenient option for obesity treatment alongside injectable forms and competitors like Lilly's orforglipron, with similar efficacy and side effects, and potential cost considerations.
The FDA has approved the first oral GLP-1 pill for obesity from Novo Nordisk, expected to launch in early 2026, offering a new treatment option that could expand access and compete with Eli Lilly in the booming weight loss drug market.
Abbott's Volt™ Pulsed Field Ablation System has received FDA approval to treat atrial fibrillation, offering a minimally invasive, effective, and safer option for patients, with clinical trials demonstrating strong safety and efficacy results.
Cytokinetics received FDA approval for its first drug, Myqorzo, to treat obstructive hypertrophic cardiomyopathy, ending a 27-year R&D drought for the company. The drug will compete with a similar medication from Bristol Myers Squibb and is expected to launch in late January.
Cytokinetics announced FDA approval of MYQORZO (aficamten), a drug for treating adults with symptomatic obstructive hypertrophic cardiomyopathy, based on positive Phase 3 trial results showing improved exercise capacity and symptoms, with safety monitored due to heart failure risk.
The FDA has approved the drug Addyi for treating hypoactive sexual desire disorder in women under 65 who are postmenopausal, expanding its use beyond premenopausal women, with experts discussing its effects, side effects, and alternative approaches for low libido during menopause.
The FDA approved RYBREVANT FASPRO™, a subcutaneous therapy for EGFR-mutated NSCLC, offering faster, more convenient treatment with fewer reactions compared to IV, and demonstrating improved survival outcomes when combined with LAZCLUZE® in first-line treatment.
